4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024669
CHIEF FINANCIAL OFFICER sold 521 shares at $27.54 ($14,347)
- CHIEF FINANCIAL OFFICER acquired 521 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-01 | Option exercise 10b5-1 | +521 | $2.48 | $1,292 | 521 | D |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-01 | Sale 10b5-1 | −521 | $27.54 | $14,347 | 0 | D |
| Derivatives | |||||||
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-01 | Option exercise · Stock Option (right to buy) 10b5-1 | −521 | 192,358 | D | ||
| Open-market sales · 521 sh · avg $27.54 · $14,347 | |||||||
Loading xslF345X05/form4-10032024_101051.xml…